Angela Madeleine Krackhardt

Prof. Dr. Angela Madeleine Krackhardt

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2016 in Nature Communications
Verified
Journal Article
Open access
PDF file
MBMichal Bassani-Sternberg
Michal Bassani-Sternberg
EBEva Bräunlein
Eva Bräunlein
RKRichard Klar
Richard Klar
TEThomas Engleitner
Thomas Engleitner
PSPavel Sinitcyn
Pavel Sinitcyn
AKAngela Madeleine Krackhardt
Angela Madeleine Krackhardt
Although mutations may represent attractive targets for immunotherapy, direct identification of mutated peptide ligands isolated from human leucocyte antigens (HLA) on the surface of native tumour tissue has so far not been successful. Using advanced mass spectrometry (MS) analysis, we survey the melanoma-associated immunopeptidome to a depth of 95,500 patient-presented peptides. We thereby discover a large spectrum of attractive target antigen candidates including cancer testis antigens and phosphopeptides. Most importantly, we identify peptide ligands presented on native tumour tissue samples harbouring somatic mutations. Four of eleven mutated ligands prove to be immunogenic by neoantigen-specific T-cell responses. Moreover, tumour-reactive T cells with specificity for selected neoantigens identified by MS are detected in the patient’s tumour and peripheral blood. We conclude that direct identification of mutated peptide ligands from primary tumour material by MS is possible and yields true neoepitopes with high relevance for immunotherapeutic strategies in cancer.

7 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
MWMathias Wilhelm
Mathias Wilhelm
DZDaniel P. Zolg
Daniel P. Zolg
MGMichael Graber
Michael Graber
SGSiegfried Gessulat
Siegfried Gessulat
TSTobias Schmidt
Tobias Schmidt
BKBernhard Kuster
Bernhard Kuster
Characterizing the human leukocyte antigen (HLA) bound ligandome by mass spectrometry (MS) holds great promise for developing vaccines and drugs for immune-oncology. Still, the identification of non-tryptic peptides presents substantial computational challenges. To address these, we synthesized and analyzed >300,000 peptides by multi-modal LC-MS/MS within the ProteomeTools project representing HLA class I & II ligands and products of the proteases AspN and LysN. The resulting data enabled training of a single model using the deep learning framework Prosit, allowing the accurate prediction of fragment ion spectra for tryptic and non-tryptic peptides. Applying Prosit demonstrates that the identification of HLA peptides can be improved up to 7-fold, that 87% of the proposed proteasomally spliced HLA peptides may be incorrect and that dozens of additional immunogenic neo-epitopes can be identified from patient tumors in published data. Together, the provided peptides, spectra and computational tools substantially expand the analytical depth of immunopeptidomics workflows.

3 July 2013 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
MNMagdalena Nauerth
Magdalena Nauerth
BWBianca Weißbrich
Bianca Weißbrich
RKRobert Knall
Robert Knall
TFTobias Franz
Tobias Franz
GDGeorg Dössinger
Georg Dössinger
DBDirk H Busch
Dirk H Busch
A Strep tamer-based k off rate assay identifies T cells with high protective capacity for the adoptive transfer.

6 March 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
MHMichael Hiltensperger
Michael Hiltensperger
AKAngela Madeleine Krackhardt
Angela Madeleine Krackhardt
Adoptive cell therapy (ACT) has seen a steep rise of new therapeutic approaches in its immune-oncology pipeline over the last years. This is in great part due to the recent approvals of chimeric antigen receptor (CAR)-T cell therapies and their remarkable efficacy in certain soluble tumors. A big focus of ACT lies on T cells and how to genetically modify them to target and kill tumor cells. Genetically modified T cells that are currently utilized are either equipped with an engineered CAR or a T cell receptor (TCR) for this purpose. Both strategies have their advantages and limitations. While CAR-T cell therapies are already used in the clinic, these therapies face challenges when it comes to the treatment of solid tumors. New designs of next-generation CAR-T cells might be able to overcome these hurdles. Moreover, CARs are restricted to surface antigens. Genetically engineered TCR-T cells targeting intracellular antigens might provide necessary qualities for the treatment of solid tumors. In this review, we will summarize the major advancements of the CAR-T and TCR-T cell technology. Moreover, we will cover ongoing clinical trials, discuss current challenges, and provide an assessment of future directions within the field.

14 July 2016 in Cancer Research
Verified
Journal Article
Open access
PDF file
SMSabine Mall
Sabine Mall
NYNahid Yusufi
Nahid Yusufi
RWRicarda Wagner
Ricarda Wagner
RKRichard Klar
Richard Klar
HBHenrique Bianchi
Henrique Bianchi
AKAngela Madeleine Krackhardt
Angela Madeleine Krackhardt
Sensitive in vivo imaging technologies applicable to the clinical setting are still lacking for adoptive T-cell–based immunotherapies, an important gap to fill if mechanisms of tumor rejection or escape are to be understood. Here, we propose a highly sensitive imaging technology to track human TCR-transgenic T cells in vivo by directly targeting the murinized constant TCR beta domain (TCRmu) with a zirconium-89 (89Zr)-labeled anti–TCRmu-F(ab')2 fragment. Binding of the labeled or unlabeled F(ab')2 fragment did not impair functionality of transgenic T cells in vitro and in vivo. Using a murine xenograft model of human myeloid sarcoma, we monitored by Immuno-PET imaging human central memory T cells (TCM), which were transgenic for a myeloid peroxidase (MPO)–specific TCR. Diverse T-cell distribution patterns were detected by PET/CT imaging, depending on the tumor size and rejection phase. Results were confirmed by IHC and semiquantitative evaluation of T-cell infiltration within the tumor corresponding to the PET/CT images. Overall, these findings offer a preclinical proof of concept for an imaging approach that is readily tractable for clinical translation. Cancer Res; 76(14); 4113–23. ©2016 AACR.

2 August 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
CTCelina Tretter
Celina Tretter
NKNiklas de Andrade Krätzig
Niklas de Andrade Krätzig
MPMatteo Pecoraro
Matteo Pecoraro
SLSebastian Lange
Sebastian Lange
PSPhilipp Seifert
Philipp Seifert
AKAngela Madeleine Krackhardt
Angela Madeleine Krackhardt
Systemic pan-tumor analyses may reveal the significance of common features implicated in cancer immunogenicity and patient survival. Here, we provide a comprehensive multi-omics data set for 32 patients across 25 tumor types for proteogenomic-based discovery of neoantigens. By using an optimized computational approach, we discover a large number of tumor-specific and tumor-associated antigens. To create a pipeline for the identification of neoantigens in our cohort, we combine DNA and RNA sequencing with MS-based immunopeptidomics of tumor specimens, followed by the assessment of their immunogenicity and an in-depth validation process. We detect a broad variety of non-canonical HLA-binding peptides in the majority of patients demonstrating partially immunogenicity. Our validation process allows for the selection of 32 potential neoantigen candidates. The majority of neoantigen candidates originates from variants identified in the RNA data set, illustrating the relevance of RNA as a still understudied source of cancer antigens. This study underlines the importance of RNA-centered variant detection for the identification of shared biomarkers and potentially relevant neoantigen candidates.